RESEARCH ARTICLE

Pathological Roles of Interleukin-22 in the Development of Recurrent Hepatitis C after Liver Transplantation

Yinjie Gao1,2☯, Hui Ren1☯, Fanping Meng3☯, Jin Li1, Eddie Cheung4,5, Hanwei Li3, Jingmin Zhao6, Hongling Liu1, Zhenwen Liu1*, Min Zhang1*

1 Liver Transplantation and Research Center, 302 Military Hospital, Beijing, China, 2 Department of Infectious Diseases, Medical School of Chinese PLA, Beijing, China, 3 Liver Cirrhosis and Research Center, 302 Military Hospital, Beijing, China, 4 California Pacific Medical Center, San Francisco, California, United States of America, 5 University of California at Davis school of medicine, Sacramento, California, United States of America, 6 Department of Pathology and Hepatology, 302 Military Hospital, Beijing, China

☯ These authors contributed equally to this work.
* gcmw2001@163.com (MZ); liuzhenwen@medmail.com.cn (ZL)

Abstract

Objective

The aim of this study was to longitudinally evaluate and analyze the role of interleukin-22-producing CD4 positive cells (IL-22) in the pathogenesis of Hepatitis C Virus recurrence after Orthotopic Liver Transplantation (HCV-OLT).

Methods

15 HCV-OLT, 15 age- and gender- matched non-HCV post-OLT (OLT) and 15 hepatitis C virus infected (HCV) patients were enrolled into our study from the liver transplantation and research center at Beijing 302 Hospital. We determined the frequencies of IL-22 using flow cytometry and expression of IL-22 mRNA using PCR in peripheral blood and liver tissue. We also divided HCV-OLT patients into rapid fibrosis progression (RFP) and slow fibrosis progression (SFP), examined IL-22 cells and analyzed the correlations between IL-22 frequencies and liver injury, fibrosis and clinical parameters. Moreover, we investigated the role of IL-22 in Human Hepatic Stellate Cells (HSCs).

Results

The levels of serum IL-22, frequencies of IL-22 producing cells in peripheral blood mononuclear cells, and expression of IL-22 mRNA and protein in the liver in the HCV-OLT group were significantly higher than that in the HCV and OLT groups. Furthermore, eight (53.3%) patients developed RFP after two years; another three patients were diagnosed liver cirrhosis. The frequencies of IL-22 were much higher in RFP compared with SFP, while no significant difference existed between OLT and SFP. Intrahepatic IL-22 positive cells were located in fibrotic areas and significantly correlated with α-smooth muscle actin (α-SMA) and fibrosis staging scores, not with grading scores and HCRVNA. In vitro, IL-22...
administration prevented HSCs apoptosis, promoted HSCs proliferation and activation, upregulated the expression of HSC-sourced growth factors including α-SMA, TGF-β and TIMP-1, and increased the production of liver fibrosis markers including laminin, hyaluronic acid and collagen type IV.

**Conclusion**

Peripheral and intrahepatic IL-22 is up-regulated and plays a pathological role in exacerbating liver fibrosis by activating HSCs in HCV-OLT patients, which may predict RFP and serve as an attractive target for anti-fibrotic therapy.

**Introduction**

Chronic hepatitis C virus (HCV) infection is a major public health problem, with an estimated 130 to 170 million people currently infected worldwide and an additional 3 to 4 million are newly infected each year [1]. The increasing burden of this epidemic is reflected by increasing prevalence of end-stage liver disease (ESLD) [2] and hepatocellular carcinoma (HCC) [3].

HCV-related disease represents the most common indication for orthotopic liver transplantation (OLT) [4], accounting for around 40% of all cases on the United States waiting list [5]. Furthermore, projections have showed a constant increase in the number of patients with HCV-related ESLD who will be listed for OLT over the next 10 years [6]. Unfortunately, almost all patients become HCV recurrence after OLT (HCV-OLT) and graft reinfection is universal after liver transplantation [7], which leads to accelerate graft loss and diminish patient survival with liver cirrhosis (LC) within five years of post-transplantation in approximately 20% and within ten years in 50% [8], compared with less than 5% of non-transplantation HCV patients. In a recent review of the Organ Procurement Transplant Network/United Network of Organ sharing (OPTN/UNOS), three-year survival was at 78% for 7,459 anti-HCV positive patients [9]. Several certain pre-OLT factors such as donor age, severity of illness, as well as recipient and donor race have been associated with an increased risk of disease progression and worse post-OLT outcomes [10–20]. After OLT, persistent low-level inflammation and loss of viral control mechanisms from systemic immunosuppression are likely causes for the severe, accelerated progression of HCV-related cirrhosis [8, 21]. In particular high-dose steroids, immunosuppressive drug combinations, a number of patient co-factors such as diabetes mellitus, baseline demographics, powerful induction treatments, and acute rejection may further promote disease progression [22]. However, the mechanisms underlying accelerated HCV-induced liver damage after OLT are poorly understood. Therefore, the pathogenesis is one of the most important issues in HCV-associated liver fibrosis research after OLT.

Liver fibrosis, developed chronic liver inflammation or injuries, is an excessive deposition of extracellular matrix (ECM) proteins in healing lesions and eventually results in LC. Hepatic stellate cells (HSCs), located in the space of Disse, are the cornerstone of liver fibrosis [23]. HSCs are activated and proliferated to myofibroblast-like cells through the epithelial mesenchymal transition (EMT) and secretion of abundant cytokines and ECM through autocrine and paracrine processes. Besides, activated HSCs also secretes tissue inhibitors of metalloproteinases (TIMPs) degrade ECM. When ECM synthesis outpaces degradation, the resulting superabundant ECM deposition can lead to liver fibrosis [24, 25]. Thus, to estimate whether a factor is protective or detrimental during liver fibrosis, researches could be started by getting a preliminary picture from in vitro co-culture/stimulation experiments with HSCs. Interestingly,
under inflammatory circumstances, activated HSCs can also behave as antigen presenting cells and elicit specific cellular responses that modulate the composition of inflammatory infiltrates and the vigor of fibro-genesis [26]. So, investigating the relationship between immune cells and HSCs in HCV-OLT liver fibrosis is a perfect cut-in point to discover indicators for the severity of disease progression.

Interleukin-22 (IL-22), acting via a heterodimer IL-10R2/IL-22R1 complex, is produced by a variety of hematopoietic cells such as innate lymphoid cells (ILCs), lymphoid tissue-inducers [27], T helper (Th) cells [28] and γδT cells [29]. Meanwhile, IL-22R1 and IL-10R2, receptors of IL-22, are expressed on specific tissues, such as hepatocytes and epithelial cells of gastro-intestine, pancreas, skin, lungs [30–32]. It has been demonstrated that through JAK and STAT molecules, IL-22 appeared to stimulate innate immunity by controlling tissue responses to inflammation, promoting the production of anti-microbial peptides, secreting mucus, releasing chemokine 8–10 and enhancing cell mobility [32–35]. Regarding liver diseases, some studies have shown that IL-22 appeared to be hepatoprotective against CCL4, concanavalin A (Con A) and FAS ligand (FasL) injury [36, 37]. On the other hand, compelling evidence also supports that IL-22 plays a potential pathogenic effect in promoting liver tumor cell growth [38, 39]. Recently, several studies have showed that IL-22 is up-regulated in hepatitis B virus (HBV) [39–41] or HCV [42–44] infection and exacerbate chronic liver inflammation and fibrosis in patients and mice [31]. In general, whether this cytokine protects against or aggravates various human diseases is depended on the nature and location of the affected tissues and local cytokine context [34, 45].

However, it is illusive regarding the roles of IL-22 in the progression of chronic liver disease, especially without available information in HCV-OLT. To address these issues, we designed this study to determine the expression, the possible relationship and mechanisms with the disease progression in HCV-OLT patients.

**Methods**

**Ethics Statement**

All patients provided the written informed consents for their blood samples, liver biopsy and their information were anonymized. Ethics approval was given by the Medical Ethics Committee of the 302 hospital and the study were in compliance with the Declaration of Helsinki. No conflict of interest during all organ transplantations. No organ trafficking involved (S1 Fig).

**Patients**

Fifteen HCV-OLT patients were enrolled into this study in the Department of Liver Transplantation and Research Center of Beijing 302 hospital from June 2010 to September 2014. Data were collected and analyzed on October 2014. All authors listed who were approved by the Medical Ethics Committee of the 302 Hospital, had access to identifying information during or after data collection. All the patients were HCVRNA positive without HCC or other diseases before OLT. No anti-viral therapy before and after transplantation. HCV recurrence was identified HCVRNA positive by quantitative Polymerase Chain Reaction (PCR) (detection limit of 100 IU/mL), anti-HCV Ab positive by Enzyme Linked Immunosorbent Assay (ELISA) and liver histology showing diagnostic pathologic features. Patients were at least six months post-OLT to avoid confounding effect of early post-OLT ischemia-reperfusion injury and surgical complication. Liver biopsies were performed at HCV recurrence and again around two years after recurrence to monitor the progression of diseases. The healthy control group consisted of 15 age- and gender- matched non-HCV post-OLT. Most of the OLT patients underwent induction with methylprednisolone, which was followed by tacrolimus (FK506) and
mycophenolate mofetil. Patients between two groups had no significant difference in the median follow-up time and plasma concentration of FK506. The disease control group with similar gender and age distribution to HCV-OLT group was composed of 15 HCV patients, which hadn’t received any antiviral or immunomodulatory therapy. Liver histological tests were conducted in OLT patients for routine follow-up and HCV patients for pathological evaluation. Table 1 lists the clinical and pathological features of the whole patients. In addition to the tissues used for pathological evaluation and embedded for in situ immunohistochemical staining, liver biopsy were immediately frozen and stored in liquid nitrogen for extraction of total RNA and isolation of liver-infiltrating lymphocytes (LILs).

**Enzyme Linked Immunosorbent Assay (ELISA)**

IL-22 (Cat. #D2200, R&D, Minneapolis, MN, US) in serum samples and liver fibrosis markers including Laminin (LN), Hyaluronic Acid (HA) and Collagen type IV (COL IV) (Yuande Biotech, Beijing, China) in the supernatant of in vitro cultures were measured by ELISA kits according to the manufacturer’s instructions in triplicate.

**Isolation of LILs**

Liver biopsy was homogenized for the isolation of LILs using methods previously described [31, 45]. Briefly, liver tissues were whittled into small pieces after washing with Hank’s solution, and then transferred into Dounceglass tissue grinder and homogenized by gently pestle until no tissue is visible. Dissociated cell suspension was passed through a 70μm Nylon mesh cell strainer (BD Labware) and underlaid onto Ficoll–Hypaque separation solution. LILs were then isolated by density gradient centrifugation.

**Flow Cytometric Analysis**

FITC-conjugated Mouse anti-Human CD4 (FITC-CD4) (Cat. 11–0049), PE-conjugated Mouse anti-Human IL-22 (PE-IL-22) (Cat. 12–7229), and Intracellular Fixation/Permeabilization Buffer Set (Cat. 88–8824) were purchased from eBioscience (San Diego, CA, US).

For intracellular IL-22 cells staining, fresh peripheral blood (200ul) and LILs were stimulated with 100 ng/mL phorbol myristate acetate and 1 μg/mL ionomycin (both from Sigma, St. Louis, MO, US) in 800ul RPMI-1640 (Invitrogen, Carlsbad, CA, US) supplemented with 10% heat-inactivated fetal calf serum (FCS) (Gibco, Grand Island, NY, US) for 6h at 37°C in

**Table 1. Clinical characteristics in different groups.**

|                  | OLT  | HCV  | HCV-OLT |
|------------------|------|------|---------|
| Number (n)       | 15   | 15   | 15      |
| Age (years)      | 44.7±11.9 | 41.6±9.4 | 43.5±13.2 |
| Gender (male/female) | 12/3 | 12/3 | 12/3    |
| ALT (U/L)        | 24.6±3.1 | 63.2±6.5 | 76.13±5.8 |
| HCV RNA (Log 10 IU/mL) | NA  | 7.19±0.17 | 5.6±0.20  |
| HCV Genotype (1b/2a) | NA  | 8/7  | 9/6     |
| FK506 (ng/mL)    | 7.7±1.2 | NA   | 7.4±0.9  |
| Follow-up after OLT (years) | 29.7±5.6 | NA   | 28.4±6.5 |

NA, not applicable; ALT, Alanine aminotransferase; Normal values: ALT, 0–40U/L; Hepatitis C Virus infection (HCV), Hepatitis C Virus recurrence after orthotopic liver transplantation (HCV-OLT), Control cases after orthotopic liver transplantation (OLT)
5% CO₂ environment. 10 mg/mL Brefeldin A solution (Tocris Cookson, Bristol, UK) was added during the first hour of incubation. The cells were stained surface markers with FITC-CD4, then fixed, permeabilized, and finally stained intracellular markers with PE-IL-22. Using BD fluorescence-activated cell sorting (FACS) Canto™ II and FlowJo software (TreeStar, Ashland, OR, US) to analyze the cells and the data.

RNA Isolation and Real-Time PCR (RT-PCR)

Total RNA was extracted using TRIZOL reagent (Invitrogen, Carlsbad, CA, US). Reverse transcription was produced using the SuperScript™ II Reverse Transcriptase (Invitrogen) and quantitative RT-PCR were conducted with SYBR Green PCR master mix (Applied Biosystems, Foster City, CA, US) following manufacturer’s instructions. Then samples were performed using 7500 RT-PCR System (Applied Biosystems) and assessed in triplicate. Primers for IL-22, α-SMA, TGF-β, TIMP-1 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were shown in Table 2.

Liver Biopsy Measurements

Percutaneous liver biopsies were performed and samples were stained with hematoxylin and eosin, Masson’s trichrome and reticulin staining. The degree of hepatic inflammation and fibrosis was graded using the modified histology activity index (HAI) described by Scheuer [46], which classifies liver fibrosis as absent (F0), restricted to the portal tract (F1), peri-portal or portal-portal septa with intact architecture (F2), bridging fibrosis with architectural distortion but no obvious cirrhosis (F3), and cirrhosis (F4). We defined rapid fibrosis progression (RFP) as liver fibrosis extending beyond the portal tracts (F2-F4) at biopsy 2 (second liver biopsy around two years after HCV recurrence), while slow fibrosis progression (SFP) as fibrosis absent or minimal fibrosis (F0-F1). Mean interval from biopsy 1 to biopsy 2 is 22.7±3.6 months. The minimal acceptable size of liver biopsy was considered 5μm.

Immunolocalization of IL-22 and α-SMA

Paraffin-embedded, formalin-fixed human liver tissues were incubated with anti-IL-22 (ab18499, abcam, Cambridge, MA, US) or α-SMA antibody (ab7817, abcam) overnight at 4°C followed by heat mediated antigen retrieval with sodium citrate buffer (pH 6.0, 0.1 mol/L) for 20mins and blocking endogenous peroxidase activity with 0.3% H₂O₂. Revelation of primary antibody was carried out using horseradish peroxidase (HRP)-conjugated rabbit polyclonal anti-mouse (ab6728, abcam), secondary antibody followed by diamino-benzidine (DAB) and

Table 2. Sequences of oligonucleotides used as primers.

| Target gene | Sequence (5’-3’) |
|-------------|------------------|
| IL-22       | Forward TGCATTTGACCAGAGCAAAG Reverse AGTTTGCGCTCCATCCTTCC |
| α-SMA       | Forward CCGACCGAATGCAGAAGGA Reverse ACAGAGTATTGGTGGCTCC |
| TGF-β       | Forward CCCAGCATCTGCAAAGCTC Reverse GTCAATGTACAGCTGCCGA |
| TIMP-1      | Forward CTGTTGTTGCTGGCTGCTGATA Reverse CGTCCACAAAGCATTAGT |
| GAPDH       | Forward GAAGGTGAAGGTCGGAGT Reverse GAAGATGGTGATGGGATTTC |

doi:10.1371/journal.pone.0154419.t002
haematoxylin coloration. Double staining was performed with 3-amino-9-ethyl-carbazole (red color) for IL-22 and BCIP/ NBT (indigo color) for CD4. Positively stained cells were counted at high-power field (hpf, ×400) according to described protocols [47].

Western Blotting

Liver samples lysis, protein extraction and western blot analysis were performed as previously described [47]. Detection of IL-22 protein was used with mouse anti-Human IL-22 (1 ug/ml, Cat. #AF782, R&D, Minneapolis, MN, US). Protein loading was normalized to GAPDH. The ratio of IL-22 to GAPDH was calculated as the relative quantification.

Human Hepatic Stellate Cells (HSCs) Stimulation

HSCs, obtained from liver specimens of patients with nonparasitic hepatic cysts who had undergone surgical resections, were isolated, cultured and prepared using methods previously described [48–51]. HSCs cells were directly co-cultured in a U-bottom 96-well plates in triplicate with or without IL-22 at various concentrations (20, 40 ng/mL, PeproTech, London, UK). After incubation for 48h and 72h, cell pellets and supernatants were harvested by centrifugation at 10,000 rpm for 5mins and cell pellets placed in RNALater solution (Ambion), then both cryopreserved at -80°C. Later, the cell pellets were evaluated the expression of α-SMA, TGF-β and TIMP-1 mRNA and supernatant were determined collagen production including LN, HA and COL IV by ELISA.

HSCs Proliferation and Apoptosis

HSCs were incubated with or without IL-22 at various concentrations (20, 40 ng/mL) for 48h and 72h in the 96-well plates in triplicate. Then cells proliferation was analyzed by testing the concentration of formazan in supernatants using a Cell Counting Kit-8 (CCK-8) commercial kit (Dojindo, Kuma-moto, Japan).

Soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (20 ng/mL) was added into medium for 6h after incubation of HSCs with or without IL-22 (20 ng/mL) for 48h. Then, cells were resuspended with binding buffer (10mM HEPES/NaOH, pH 7.4, 140mM NaCl, 2.5mM CaCl2) and incubated with Annexin V and 7-aminoactinomycin D (7-AAD) (Biolegend, San Diego, CA, US) for 15mins before analysis using FACS.

Statistical Analysis

All data were analyzed using SPSS 16.0 statistical software (Version 16.0, SPSS Inc., Chicago, IL, US). Results were expressed as means ± SD. Statistical comparisons between two groups used a Mann-Whitney non-parametric U test, whereas comparisons between the same individual used a Wilcoxon’s matched-pairs t test. The Kruskal-Wallis H nonparametric test was used for multiple comparisons between different groups. The Spearman’s rank correlation test was used to assess the relationship of immune factors and clinical characters. Two-sided P < 0.05 was considered statistically significant.

Result

Clinical Characteristics of Different Outcomes of HCV-OLT Patients

Table 3 listed the basic characteristics of HCV-OLT patients pre and postoperatively. Cellular rejection was excluded by histological examination. Mean interval from biopsy 1 to biopsy 2 was 22.7±3.6 months. HCVRNA reappeared within one year and liver biopsy showed absent or minimal fibrosis (F0-F1). However, after two years, eight (53.3%) patients developed severe
liver fibrosis; another three patients resulted in liver cirrhosis. The titers of HCVRNA of recurrence were higher than that before OLT (5.60 ±0.20 versus 6.75 ±0.22, p = 0.0006) and significantly lower than that after two years (6.75 ± 0.22 versus 7.39 ±0.16, p = 0.0259). ALT also elevated with progression of HCV-OLT. With respect to genotypes, 9 patients had genotype 1b, and the remaining 6 had genotype 2a. The titers of HCV RNA were similar between HCV-OLT patients with genotype 1b and 2a (p = 0.2874).

Serum and Peripheral IL-22 Levels Increased in HCV-OLT Patients

To investigate the expression of IL-22 in different groups, we analyzed the serum IL-22 using ELISA and peripheral IL-22 cells subsets in the total CD4+T cells population using flow cytometry. As shown in Fig 1A, there were significantly higher levels of serum IL-22 in HCV-OLT patients compared to OLT (44.85±3.76 versus 18.12±2.87 pg/ml; p<0.0001) and HCV patients (26.01±3.80 pg/ml; p = 0.0015). No difference between OLT and HCV patients (p = 0.1087). Our previous experiment had determined that CD4 cells were the main cell population dedicated to IL-22 production [31, 52]. Hence, we assessed the characteristics of peripheral IL-22 cells in the total CD4+T cells (Fig 1B) and found that in both HCV-OLT and HCV, the frequencies of IL-22 cells increased significantly compared with OLT (3.41±0.18% versus 1.08 ±0.12% pg/ml, p<0.0001; 1.62±0.15% versus 1.08±0.12% pg/ml, p = 0.0074) and the IL-22 in HCV-OLT was significantly higher than that in HCV (p<0.0001) patients (Fig 1C). These results suggested that IL-22 cells were markedly accumulated in the liver tissues of HCV-OLT.

Intrahepatic IL-22 Increased in HCV-OLT and Correlated with Liver Fibrosis

Meanwhile, we also investigated the roles of IL-22 in the liver. We measured the distribution of IL-22 and the expression of gene and protein in the liver in different groups. IL-22 cells were

| Number | Pre-OLT Genotype | HCVRNA | Recurrence (biopsy 1) | Post-OLT HCVRNA | After about two year (biopsy 2) |
|--------|-----------------|--------|-----------------------|----------------|---------------------------------|
|        |                 |        | time | ALT | S | HCVRNA |          | S | ALT | HCVRNA |
| 1      | 1b              | 5.87   | 9    | 58  | 1 | 6.49   | 1         | 132 | 7.77 |
| 2      | 1b              | 5.02   | 11   | 97  | 0 | 6.24   | 3         | 119 | 6.98 |
| 3      | 2a              | 5.48   | 12   | 82  | 1 | 7.18   | 1         | 94  | 7.96 |
| 4      | 1b              | 6.20   | 7    | 76  | 0 | 6.98   | 4         | 157 | 7.48 |
| 5      | 2a              | 4.67   | 8    | 71  | 0 | 5.13   | 1         | 102 | 7.51 |
| 6      | 2a              | 4.42   | 11   | 64  | 1 | 5.32   | 3         | 96  | 6.87 |
| 7      | 1b              | 6.81   | 6    | 85  | 1 | 7.35   | 4         | 87  | 8.03 |
| 8      | 1b              | 6.99   | 8    | 89  | 1 | 8.00   | 2         | 184 | 6.20 |
| 9      | 1b              | 6.03   | 9    | 56  | 0 | 6.87   | 1         | 73  | 7.13 |
| 10     | 2a              | 5.10   | 7    | 51  | 0 | 6.98   | 2         | 105 | 6.49 |
| 11     | 1b              | 4.44   | 10   | 115 | 1 | 7.51   | 4         | 148 | 7.35 |
| 12     | 2a              | 5.67   | 7    | 93  | 0 | 5.86   | 2         | 81  | 7.18 |
| 13     | 1b              | 5.77   | 8    | 48  | 0 | 6.86   | 1         | 88  | 8.14 |
| 14     | 1b              | 5.50   | 8    | 92  | 1 | 6.47   | 1         | 104 | 7.24 |
| 15     | 2a              | 5.97   | 7    | 65  | 0 | 7.96   | 1         | 115 | 8.51 |
accumulated mainly in portal areas (Fig 2A) and produced by CD4 cells (Fig 2B). The expressions of IL-22 in the HCV-OLT group were significantly higher than those in the OLT (28.85 ±2.50 versus 8.52 ±1.11, p < 0.0001) and HCV (12.00 ±1.20, p < 0.0001) groups (Fig 2C). The expressions of IL-22 mRNA were also significantly up-regulated in the HCV-OLT liver than those in either OLT (3.68 ±0.30 versus 1.87 ±0.18, p < 0.0001) or HCV (2.18 ±0.24, p = 0.0007) liver, while no significant difference between OLT and HCV group (P = 0.3118) (Fig 2D).

Next, IL-22 proteins were detected by western blotting in the liver. They had the same change tendency with the gene expressions (Fig 2E).

Next, to further detect the relationship between roles of IL-22 and the development of HCV infection, we analyzed the correlations between IL-22 frequencies and liver injury and fibrosis in HCV-OLT and HCV patients. As shown in Fig 2, a significantly positive correlation was found between IL-22 cells frequencies and α-SMA (Fig 2F) (P = 0.0003) or fibrosis staging (Fig 2G) (P = 0.0034). No correlation was found between IL-22 cells frequencies and grading score (P = 0.0631) (Fig 2H) or HCV RNA (P = 0.1345) (Fig 2I).
Increase of IL-22 Cells Was Associated with Rapid Fibrosis Progression in HCV-OLT

We also divided HCV-OLT patients into RFP (F2-F4) and SFP (F0-F1) group according to the fibrosis score at biopsy 2. No significane existed in recipient demographics, OLT-related parameters and hepatitis C viral parameters between RFP and SFP (Table 4). Eight (53.3%) patients developed RFP after two years; another three patients were diagnosed liver cirrhosis.
As shown in Fig 3, there were no fibrosis in the liver when HCV recurrence (Fig 3A). However, as illustrated by Masson trichrome and reticulin staining (Fig 3B), the progressive fibrosis presented after two years of recurrence. We also found more IL-22 cells were significantly infiltrated in RFP liver tissues (Fig 3D) compared with SRF (Fig 3C), and mainly accumulated in fibrotic septa with the progression of fibrosis. The frequencies of IL-22 were much higher in RFP compared with SFP (39.13±1.90 versus 12.31±1.70, p < 0.0001) (Fig 3E). However, there was no significant difference between OLT and SFP groups (12.31 ±1.70 versus 8.52 ±1.11, p = 0.0720). This indicated the possibility that IL-22 cells may had a cell-to-cell contact with activated HSCs. Therefore, we used two colors immunofluorescence to determine IL-22R and α-SMA expression. Results showed IL-22R and α-SMA was co-expressed in the liver tissues of HCV-OLT patients (Fig 3F).

### IL-22 Promotes HSCs Proliferation and Activation and Inhibits Apoptosis In Vitro

Given IL-22 cells were co-localized with α-SMA+ HSCs in the portal area and positively correlated with liver fibrosis and progression of HCV-OLT, we further investigated the influence of IL-22 in regulating HSCs. We found that Cycloheximide (CHX) could induce Annexin V+7-AAD- HSCs apoptosis in vitro. Interestingly, the addition of IL-22 (20 ng/mL) significantly inhibited HSCs apoptosis (Fig 4A and 4B) following a 4h incubation with CHX that was markedly reduced in IL-22 pre-treated HSCs (13.61±0.97 versus 6.98±0.70, p<0.0001). Meanwhile, we performed contact co-cultures of primary HSCs in intermediate state respectively with IL-22 at various concentrations for 48h or 72h. Results showed there were significances different in the concentration of formazan which represented proliferation in supernatants between HSCs with or without IL-22 at various concentrations (20, 40 ng/mL) for 48h or 72h (Fig 4C). We also assessed the mRNA expression of HSC-sourced growth factors including α-SMA, TGF-β and TIMP-1 in HSCs, and the concentration of liver fibrosis markers including LN, HA and Collagen IV in the supernatants with or without IL-22 (20, 40 ng/mL) for 48h or 72h. Data indicated that, compared with medium, IL-22 cells dramatically promoted the mRNA expression of α-SMA, TGF-β and TIMP-1 (Fig 5A) and the production of LN, HA and Collagen IV (Fig 5C). Also, the roles were significant stronger with the increasing amount of IL-22 and the prolongation of time. Western blotting also showed the expression of α-SMA and Collagen IV had the same change tendency with their gene expressions.

| Table 4. Comparison of recipient demographics, OLT-related parameters, and hepatitis C viral parameters between RFP and SFP patients. |
|-------------------------------------------------|-----------------|-----------------|-----------------|
|                RFP (n = 8)                      | SFP (n = 7)    | P Value         |
| Recipient Age at OLT  | 44.8±11.4      | 42.1±12.7       | 0.6713          |
| Gender (M/F)         | 5/1            | 7/2             | 0.6593          |
| BMI                 | 24.3±7.6       | 22.7±9.3        | 0.7196          |
| OLT-related parameters |                |                 |                 |
| Donor age           | 47.8±12.1      | 39.2±11.5       | 0.1835          |
| Cold ischemia time  | 7.8±2.4        | 7.4±2.2         | 0.7433          |
| Warm ischemia time  | 38.1±12.7      | 37.8±13.9       | 0.9658          |
| Immunosuppression   | 8.1±0.8        | 7.3±1.3         | 0.1687          |
| HCV parameters      |                |                 |                 |
| Genotype (1b/2a)    | 5/3            | 4/3             | 0.7513          |
| HCVRNA when recurrence | 6.78±0.32     | 6.71±0.32       | 0.8782          |

doi:10.1371/journal.pone.0154419.004
Discussion

IL-22, acting as a potent immune mediator, plays vital roles in many liver diseases [31, 36–44]. In current study, we firstly investigated the effect of IL-22 in the patients with HCV recurrence after OLT. The major finding are: (1) Peripheral and intrahepatic expression of IL-22 were significantly elevated in OLT-HCV. (2) IL-22 was associated with the rapid fibrosis progression in HCV-OLT. (3) The up-regulation of IL-22 may further active HSCs to release extracellular matrix, a process likely to be implicated in liver fibrosis.

HCV-related disease remains the leading indication for liver transplantation and HCV recurrence is universal after OLT, especially in the patients who had high viremia before transplant. In general, evasion of the innate immune system is the reason to chronic HCV infection.
and response of priming of adaptive immune modulate the severity of fibrosis progression. Serum HCVRNA reach levels of pre-OLT titers usually within 4 days after surgery, increase and peak around month 3, and finally attain levels 10- to 100-fold around one year [53]. Liver fibrosis progression during immunosuppressive therapy is extremely accelerated and more rapid than that in non-transplant patients, probably due to a compromised virus-specific Th1 CD4 immune response [54]. In our results, after HCV recurrence, HCVRNA and ALT increased persistently with the progression of HCV-OLT and finally led to the development of liver fibrosis after two years, even three patients resulted in liver cirrhosis.

IL-22, a member of IL10 cytokine family, was discovered in 2000 [55]. Many immune cells, such as CD4 T, CD8 T, NK/NKT, γδT, and macrophages cells, can generate IL-22. Among them, CD4+ T cells are the major sources of IL-22 production in both the liver and peripheral blood [28, 34, 56]. Different from other interleukins, IL-22 is a unique cytokine that regulate the inflammation in IL-22 specific tissues and no any direct roles on immune because its receptors are not expressed on immune cells [32]. The potential role of IL-22 in liver diseases has been intensively studied. In murine models, IL-22 attenuated liver injury [37, 57], prevented hepatic failure [58] and improved hepatic steatosis [57], which suggest a tissue protective function of IL-22 in hepatic disorder. However, the pathophysiological relevance and prognostic
potential of serum IL-22 in patients with liver diseases of various etiologies is less clear. Different animal models and patients’ condition lead to different result. In HCV infected patients, many studies reported IL-22 played a pathogenic role in the development of chronic liver diseases [42, 43, 45, 52]. In resolved HCV infection, Matthew et al. [59] found significant production of IL-22 was associated with HCV-antigen-specific induction of CD4+ T cell proliferation compared with chronic HCV infection, which suggested IL-22 could be involved in HCV clearance. Although IL-22 doesn’t play direct roles on HCV replication [42], IL-22 productions maybe result in a proinflammatory response to eliminate virus by STAT3 activation and its anti-apoptotic and regeneration promotion effect during HCV recurrence after OLT, especially when HCV virus rapidly increase in immunosuppressive environment. Although several researchers have found IL-22 were up-regulated in HCV-infected patients [42–44, 52], the roles remain obscure in HCV recurrent patients after OLT. Here, we clearly demonstrated that the levels of serum and peripheral blood IL-22 were significantly increased in HCV-OLT patients. In the liver, IL-22-producing cells were accumulated mainly in portal areas and produced by CD4 cells. The expressions of IL-22 in the HCV-OLT were significantly higher than those in the OLT and HCV and IL-22 mRNA was also up-regulated in liver.

In addition, there are also many different correlations between hepatic IL-22 and liver fibrosis. In mouse experiment, Kong et al. [60] reported IL-22 had anti-fibrotic effects in CCL4 mouse models, while Zhao et al. [31] reported pro-fibrotic functions in the HBV Tg mouse model. The difference is due to different models. In Kong’s study, liver fibrosis was induced by acute liver damage resulting from CCL4 administration. IL-22 attenuated acute-damage-driven fibrosis through reducing acute hepatocyte injury. However, in Zhao’s study, progressive liver fibrosis in HBV Tg mouse model they used was driven by T-cells mediated immune response. Overexpression of IL-22 accelerated fibrosis through enhancing chronic inflammation. The roles of anti or pro fibrotic IL-22 depend on its roles of inflammatory protection or damage. In clinic studies, Xiang X et al. reported in chronic hepatitis B virus infected patients, IL-22 and

Fig 5. IL-22 in vitro induces the activation of HSCs. (A) The mRNA expression of α-SMA, TGF-β and TIMP-1 in different HSCs groups with or without IL-22 at various concentrations (20, 40 ng/mL) for 48h or 72h. (B) The expression of α-SMA also had the same change with mRNA in different concentrations and time points. (C) The cytokine concentration of laminin, hyaluronic acid and collagen type IV in the supernatants were determined at various concentrations (20, 40 ng/mL). (D) The expression of collagen IV was consistent with gene change.

doi:10.1371/journal.pone.0154419.g005
non-ELR-CXC chemokines synergistically provided protection in liver inflammation and fibrosis [41], whereas other clinic studies revealed elevated systemic IL-22 were relevant with the progression of liver fibrosis [31, 52, 61]. In our study, we found IL-22 were significantly positively correlated with α-SMA and fibrosis staging, though not correlated with grading score and HCVRNA. The frequencies of IL-22, which mainly infiltrated in fibrotic septa, were much higher in RFP compared with SFP, whereas there was no significant difference between OLT and SFP. This indicated IL-22 was positively correlated with liver fibrosis and progression in HCV-OLT patients.

Interestingly, we also found IL-22 immunofluorescence staining was co-localized with α-SMA, a marker for activated HSCs, in the portal area in RFP. Over the past decade, the activation of HSCs into myofibroblasts has always been critical to liver fibrogenesis [23] and recent study revealed that quiescent and activated HSCs could express high levels of IL-22R1 [31, 52, 60, 62, 63]. We therefore designed co-cultures of IL-22 with HSCs to explore exact effects of IL-22 cells responses on HSCs activation and proliferation. In the present study, we have demonstrated that the infiltration of IL-22 cells could exacerbate the progression of liver fibrosis in HCV-OLT patients via the stimulation of HSCs. IL-22 have the potential of promoting HSCs proliferation and activation, and inhibiting apoptosis in vitro. Similar to other recent studies [36, 37, 60, 64], we found that IL-22 (20 ng/mL) significantly inhibited HSCs cells apoptosis following a 4h incubation with CHX that was markedly reduced in IL-22 pre-treated HSCs. The reason may be IL-22 activates STAT3, which acts as a key transcriptional factor for cell survival via the induction of the anti-apoptotic genes Bcl-2 and Bcl-xl [60]. Additionally, IL-22 also showed a mitogenic effect on HSCs, which is consistent with other study revealing that IL-22 can promote hepatocyte and liver stem cell proliferation (60, 64). Lastly, our data demonstrated that stimulation of HSCs with IL-22 dramatically resulted in the up-regulation of α-SMA, TGF-β and TIMP-1 mRNA expression and the production of laminin, hyaluronic acid and collagen type IV, thus promoting liver fibrosis progression. Also, the roles were significant stronger with the increasing amount of IL-22 and the prolongation of time. Recent studies [31, 52, 65] on HBV and HCV patients showed increased hepatic IL-22 may induce Th17 migration to aggravate liver fibrosis. So, given the effect of IL-22 between its dual protective and pathogenic roles in human liver diseases, future studies should be focused on the differential roles of IL-22 and IL17 in promoting liver inflammation and fibrosis at various stages of HCV-OLT.

Conclusion

In conclusion, we suggested that the IL-22 was increased and had significant effects on fibrosis progression in HCV-OLT patients for their influence on liver injury and HSCs function. The characterization of the IL-22 in HCV-OLT by our work paves the way for future researches about fibrosis and immune pathways.

Supporting Information

S1 Fig. 302 Military Hospital of China Medical Ethics Committee Clinical Study Review Decision. (TIF)

Acknowledgments

We would like to thank all of the patients enrolled in this study for their kind understanding and support.
Author Contributions
Conceived and designed the experiments: YG HR JL ZL MZ. Performed the experiments: YG HR FM. Analyzed the data: YG. Contributed reagents/materials/analysis tools: H. Li H. Liu JZ. Wrote the paper: YG EC.

References
1. Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44(1): 20–29. PMID: 14681338
2. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States Hepatology. 2000 Mar; 31(3): 777–82. PMID: 10706572
3. El-Serag HB, Mason AC. Risk factors for primary liver cancer in the United States. Arch Intern Med 2000; 160(21): 3227–30. PMID: 11088082
4. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001; 35(5): 666–78. PMID: 11690716
5. Szabó E, Lotz G, Páska C, Kiss A, Schaff Z. Viral hepatitis: new data on hepatitis C infection. Pathol Oncol Res 2003; 9(4): 215–21. PMID: 14688826
6. Biggins SW, Bambha KM, Terrault NA, Inadomi J, Shiboski S, Dodge JL, et al. Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl 2012; 18(12): 1471–8. doi: 10.1002/lt.23551 PMID: 23008049
7. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103(1): 317–22. PMID: 1377143
8. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32(4): 852–8. PMID: 11003634
9. Available: http://www.unos.org. Accessed January 2014.
10. Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38(1): 34–41. PMID: 12829984
11. Ananthakrishnan AN, Saeian K. Racial differences in liver transplantation outcomes in the MELD era. Am J Gastroenterol 2008; 103(4): 901–10. doi: 10.1111/j.1572-0241.2008.01809.x PMID: 18371131
12. Berenguer M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl 2003; 9(11): S44–7. PMID: 14586894
13. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6(4): 783–90. PMID: 16539636
14. Gane EJ, Nacumov NV, Qian KP, Mondelli MU, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 10(1): 167–77.
15. Layden JE, Cofler SJ, Grim SA, Fischer MJ, Lucey MR, Clark NM. Impact of donor and recipient race on survival after hepatitis C-related liver transplantation. Transplantation 2012; 93(4): 444–9. doi: 10.1097/TP.0b013e3182406a94 PMID: 22277982
16. Neff GW, Kemmer N, Kaiser T, Zacharias V, Majoras N, Safdar K. Outcomes in adult and pediatric liver transplantation among various ethnic groups. Transplant Proc 2007; 39(10): 3204–6. PMID: 18089354
17. Nair S, Eustace J, Thuluvath PJ. Effect of race on outcome of orthotopic liver transplantation: a cohort study. Lancet 2002; 359(9303): 287–93. PMID: 11850194
18. Pang PS, Kamal A, Glenn JS. The effect of donor race on the survival of Black Americans undergoing liver transplantation for chronic hepatitis C. Liver Transpl 2009; 15(9): 1126–32. doi: 10.1002/lt.21835 PMID: 19718638
19. Saxena V, Lai JC, O’Leary JG, Verna EC, Brown RS Jr, Stravitz RT, et al. Recipient-donor race mismatch for African-American liver transplant patients with chronic hepatitis C. Liver Transpl 2012; 18(5): 524–31. doi: 10.1002/lt.22461 PMID: 22140019
20. Layden JE, Cofler S, Brown KA, Lucey MR, Te HS, Eswaran S, et al. Racial differences in fibrosis progression after HCV-related liver transplantation. Transplantation. 2012; 94(2): 178–84. doi: 10.1097/TP.0b013e318253f7fa PMID: 22743546
21. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32(4): 673–84. PMID: 10782918
22. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5(4 Suppl 1): S107–14.

23. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88(1): 125–72. doi: 10.1152/phyrev.00013.2007 PMID: 18195085

24. Veidal SS, Nielsen MJ, Leeming DJ, Karsdal MA. Phosphodiesterase inhibition mediates matrix metalloproteinase activity and the level of collagen degradation fragments in a liver fibrosis ex vivo rat model. BMC Res Notes 2012; 5(1): 686. doi: 10.1186/1756-0500-5-686 PMID: 23249435

25. Modol T, Brice N, Ruiz de Galaretza M, García Garzón A, Iraburu MJ, Martínez-Irujo JJ, et al. Fibronectin peptides as potential regulators of hepatic fibrosis through apoptosis of hepatic stellate cells. J Cell Physiol 2015; 230(3): 546–53. doi: 10.1002/jcp.24714 PMID: 24976518

26. Sun HQ, Zhang JY, Zhang H, Zou ZS, Wang FS, Jia JH. Increased Th17 cells contribute to disease progression in patients with HBV-associated liver cirrhosis. J Viral Hepat 2012; 19(6): 396–403. doi: 10.1111/j.1365-2893.2011.01561.x PMID: 22571901

27. Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells—how did we miss them? Nat Rev Immunol 2013; 13(2): 75–87. doi: 10.1038/nri3349 PMID: 23292121

28. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203(10): 2271–2279. PMID: 16982811

29. Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov 2011; 13(1): 21–38. doi: 10.1038/nrd4176 PMID: 23478801

30. Duerr RH, Taylor KD, Brant SR, Rioux JD. Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314(5804): 1461–3. PMID: 17068223

31. Zhao J, Zhang Z, Luan Y, Zou Z, Sun Y, Li Y, ea al. Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology 2014; 59 (4): 1331–42. doi: 10.1002/hep.26916 PMID: 24677193

32. Wolk K, Witte E, Witte K, Warszawska K, Sabat R. Biology of interleukin-22. Semin Immunopathol 2013; 35(2): 171–84. doi: 10.1007/s00281-013-0316-6 PMID: 23732806

33. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28(4): 454–67. doi: 10.1016/j.immuni.2008.03.004 PMID: 18400188

34. Witte E, Witte K, Warszawska K, Sabat R, Wolk K. Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev 2010; 21(5): 365–79. doi: 10.1016/j.cytogfr.2010.08.002 PMID: 20870448

35. Zenewicz LA, Flavell RA. Recent advances in IL-22 biology. Int Immunol 2011; 23(3): 159–63. doi: 10.1093/intimm/dxr001 PMID: 21393631

36. Pan H, Hong F, Radaeva S, Gao B. Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride- and Fas ligand-induced injury via activation of STAT3, Cell Mol Immunol 2004; 1(1): 43–49. PMID: 16212920

37. Radaeva S, Sun RN, Pan HN, Hong F, Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 2004; 39(5): 1332–42. PMID: 15122762

38. Jiang R, Tan Z, Deng L, Chen Y, Xia Y, Gao Y, et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011; 54(3): 900–9. doi: 10.1002/hep.24486 PMID: 21674558

39. Park O, Wang H, Wang H, Feigenbaum L, Li H, Yin S, et al. In vivo consequences of liver-specific interleukin-22 expression in mice: implications for human liver disease progression. Hepatology 2011; 54 (1): 252–61. doi: 10.1002/hep.24339 PMID: 21465510

40. Zhang Y, Cboleigh MA, Lian JO, Huang CX, Booth CJ, Bai XF, et al. A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology 2011; 141(5):1897–906. doi: 10.1053/j.gastro.2011.06.051 PMID: 21708106

41. Xiang X, Gui H, King NJ, Cole L, Wang H, Xie Q, ea al. IL-22 and non-ELR-CXC chemokine expression in chronic hepatitis B virus-infected liver. Immunol Cell Biol 2012; 90(6): 611–19. doi: 10.1038/icb.2011.79 PMID: 21946664

42. Dambacher J, Beigel F, Zitzmann K, Heeg MH, Goke B, Diepolder HM, et al. The role of interleukin-22 in hepatitis C virus infection. Cytokine 2008; 41(3): 209–216. doi: 10.1016/j.cyto.2007.11.016 PMID: 18191408
43. Foster RG, Golden-Mason L, Rutebemberwa A, Rosen HR. Interleukin (IL)-17/IL-22-producing T cells enriched within the liver of patients with chronic hepatitis C viral (HCV) infection. Dig. Dis. Sci 2012; 57 (2): 381–89.

44. Kang YH, Seigel B, Bengsch B, Fleming VM, Billerbeck E, Simmons R, et al. CD161+(+)CD4(+) T cells are enriched in the liver during chronic hepatitis and associated with co-secretion of IL-22 and IFN-gamma. Front Immunol 2012; 3:346. doi: 10.3389/fimmu.2012.00346 PMID: 23181064

45. Cobleigh MA, Robek MD. Protective and pathological properties of IL-22 in liver disease: implications for viral hepatitis, Am J Pathol 2013; 182 (1): 21–8. doi: 10.1016/j.ajpath.2012.08.043 PMID: 23159948

46. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13(3): 372–4. PMID: 1808228

47. Gao Y, Zhang M, Li J, Yang M, Liu Y, Guo X, et al. Circulating FoxP3+ regulatory T and Interleukin17-producing Th17 cells actively influence HBV clearance in De Novo Hepatitis B Virus infected patients after orthotopic Liver Transplantation. PLoS One 2015; 10(9): e0137881. doi: 10.1371/journal.pone.0137881 PMID: 26367459

48. Vinas O, Bataller R, Sancho-Bru P, Gines P, Berenguer C, Enrich C, et al. Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology 2003; 38 (4): 919–29. PMID: 14512879

49. Yu MC, Chen CH, Liang X, Wang L, Gandhi CR, Fung JJ, et al. Inhibition of T cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology 2004; 40(6): 1312–21. PMID: 15565659

50. Liu C, Gaca MD, Swenson ES, Vellucci VF, Reiss M, Wells RG. Smads 2 and 3 are differentially activated by transforming growth factor-beta (TGF-beta) in quiescent and activated hepatic stellate cells. Constitutive nuclear localization of Smads in activated cells is TGF-beta-independent. J Biol Chem 2003; 278(13): 11721–8. PMID: 12547835

51. Li J, Qiu S, She W, Wang F, Gao H, Li L, et al. Significance of the Balance between Regulatory T (Treg) and T Helper 17 (Th17) Cells during Hepatitis B Virus Related Liver Fibrosis. PLoS ONE 2012; 7(6): e93907. doi: 10.1371/journal.pone.0093907 PMID: 22745730

52. Wu L, Liu s, Liu Y, Guo C, Li H, Li W, et al. Up-regulation of interleukin-22 mediates liver fibrosis via activating hepatic stellate cells in patients with hepatitis C. Clinical Immunology 2015; 158(1): 77–87. doi: 10.1016/j.clim.2015.03.003 PMID: 25771172

53. Garcia-Retortillo M, Forns X, Feliz A, Molinero E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35(3): 680–7. PMID: 11870384

54. Rosen HR, Hinrichs DJ, Gretchen DR, Koziel MJ, Houghton M, et al. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999; 117(4): 926–32. PMID: 10500076

55. Dumoutier L, Louahed J, Renaud JC. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol 2000; 164(4): 1814–9. PMID: 10657629

56. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009; 119(12): 3573–85. doi: 10.1172/JCI40202 PMID: 19920355

57. Ki SH, Park O, Zheng M, Morales-Ibanez O, Kolls JK, Bataller R, et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology 2010; 52(4): 1291–300. doi: 10.1002/hep.23837 PMID: 20842630

58. Xing W, Zou M, Liu S, Xu T, Gao J, Wang J, et al. Hepatoprotective effects of IL-22 on fulminant hepatic failure induced by d-galactosamine and lipopolysaccharide in mice. Cytokine 2011; 56(2): 174–8. PMID: 21842630

59. Mattei FC, Jane EL, Robert SF, David DE. In vitro antigen-specific induction of IL-22 in human subjects that resolved HCV infection. Future Virol 2012; 7(7): 719–728. PMID: 23185211

60. Kong X, Feng D, Wang H, Hong F, Bertola A, Wang FS, et al. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 2012; 56(3): 1150–9. doi: 10.1002/hep.25744 PMID: 22473749

61. Kronenberger B, Rudloff I, Bachmann M, Brunner F, Kapper L, Flimann N, et al. Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study. BMC Med 2012; 10:102. doi: 10.1186/1741-7015-10-102 PMID: 22967278

62. Xu L, Hui AY, Albanis E, Arthur MJ, O’Byrne SM, Blaner WS, et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005; 54(1): 142–51. PMID: 15591520
63. Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, Gores GJ. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis, Hepatology 2003; 37(1): 87–95. PMID: 12500193

64. Feng D, Kong X, Weng H, Park O, Wang H, Dooley S, et al. Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology 2012; 143(1): 188–98. doi: 10.1053/j.gastro.2012.03.044 PMID: 22484119

65. Eyerich S, Eyerich K, Cavani A, Schmidt-Weber C. IL-17 and IL-22: siblings, not twins, Trends Immunol 2010; 31(9): 354–61. doi: 10.1016/j.it.2010.06.004 PMID: 20691634